APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Adjuvants

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.

Selected research

Market Outlook & Growth Opportunities

Global Vaccine Adjuvants Market Outlook and Growth Opportunities 2026

25 December 2025198 pages

Choose your research edition.

Industry ResearchVaccine Adjuvants Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Adjuvants Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Vaccine Adjuvants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Adjuvants Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Adjuvants Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.

The top 5 global manufacturers of vaccine adjuvants are GSK, CSL Limited, Croda, SEPPIC, Novavax, which have a combined market share of about 55 percent. North America is the largest market, with a share about 38%, followed by Europe and Asia Pacific with the share about 27% and 22%.

This report provides an overview of the global Vaccine Adjuvants market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Vaccine Adjuvants and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine Adjuvants sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine Adjuvants market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine Adjuvants Segment by Company

GSK

CSL Limited

Croda

SEPPIC

Novavax

SPI Pharma

Phibro

SDA BIO

Invivogen

Tj Kaiwei

OZ Biosciences

Brenntag Biosector

MVP Laboratories

Zhuoyue

Aphios

Vaccine Adjuvants Segment by Type

Aluminum Adjuvant

Emulsions Adjuvant

Others

Vaccine Adjuvants Segment by Application

Human Vaccine

Veterinary Vaccine

Vaccine Adjuvants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vaccine Adjuvants status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vaccine Adjuvants market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaccine Adjuvants significant trends, drivers, influence factors in global and regions.

6. To analyze Vaccine Adjuvants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Adjuvants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine Adjuvants market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine Adjuvants industry.

Chapter 3: Detailed analysis of Vaccine Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vaccine Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vaccine Adjuvants in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaccine Adjuvants Industry Trends Table 2. Vaccine Adjuvants Industry Drivers Table 3. Vaccine Adjuvants Industry Opportunities and Challenges Table 4. Vaccine Adjuvants Industry Restraints Table 5. Global Vaccine Adjuvants Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaccine Adjuvants Revenue Share by Company (2021-2026) Table 7. Global Vaccine Adjuvants Sales Volume by Company (MT) & (2021-2026) Table 8. Global Vaccine Adjuvants Sales Volume Share by Company (2021-2026) Table 9. Global Vaccine Adjuvants Average Price (USD/Kg) of Company (2021-2026) Table 10. Global Vaccine Adjuvants Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vaccine Adjuvants Key Company Manufacturing Base & Headquarters Table 12. Global Vaccine Adjuvants Company, Product Type & Application Table 13. Global Vaccine Adjuvants Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Aluminum Adjuvant Table 18. Significant Companies of Emulsions Adjuvant Table 19. Significant Companies of Others Table 20. Global Vaccine Adjuvants Sales Volume by Type 2021 VS 2025 VS 2032 (MT) Table 21. Global Vaccine Adjuvants Sales Volume by Type (2021-2026) & (MT) Table 22. Global Vaccine Adjuvants Sales Volume by Type (2027-2032) & (MT) Table 23. Global Vaccine Adjuvants Sales Volume Share by Type (2021-2026) Table 24. Global Vaccine Adjuvants Sales Volume Share by Type (2027-2032) Table 25. Global Vaccine Adjuvants Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Vaccine Adjuvants Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Vaccine Adjuvants Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Vaccine Adjuvants Sales Value Share by Type (2021-2026) Table 29. Global Vaccine Adjuvants Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Human Vaccine Table 31. Significant Companies of Veterinary Vaccine Table 32. Global Vaccine Adjuvants Sales Volume by Application 2021 VS 2025 VS 2032 (MT) Table 33. Global Vaccine Adjuvants Sales Volume by Application (2021-2026) & (MT) Table 34. Global Vaccine Adjuvants Sales Volume by Application (2027-2032) & (MT) Table 35. Global Vaccine Adjuvants Sales Volume Share by Application (2021-2026) Table 36. Global Vaccine Adjuvants Sales Volume Share by Application (2027-2032) Table 37. Global Vaccine Adjuvants Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Vaccine Adjuvants Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Vaccine Adjuvants Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Vaccine Adjuvants Sales Value Share by Application (2021-2026) Table 41. Global Vaccine Adjuvants Sales Value Share by Application (2027-2032) Table 42. Global Vaccine Adjuvants Sales by Region: 2021 VS 2025 VS 2032 (MT) Table 43. Global Vaccine Adjuvants Sales by Region (2021-2026) & (MT) Table 44. Global Vaccine Adjuvants Sales Market Share by Region (2021-2026) Table 45. Global Vaccine Adjuvants Sales by Region (2027-2032) & (MT) Table 46. Global Vaccine Adjuvants Sales Market Share by Region (2027-2032) Table 47. Global Vaccine Adjuvants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Vaccine Adjuvants Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Vaccine Adjuvants Sales Value Share by Region (2021-2026) Table 50. Global Vaccine Adjuvants Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Vaccine Adjuvants Sales Value Share by Region (2027-2032) Table 52. Global Vaccine Adjuvants Market Average Price (USD/Kg) by Region (2021-2026) Table 53. Global Vaccine Adjuvants Market Average Price (USD/Kg) by Region (2027-2032) Table 54. Global Vaccine Adjuvants Sales by Country: 2021 VS 2025 VS 2032 (MT) Table 55. Global Vaccine Adjuvants Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Vaccine Adjuvants Sales by Country (2021-2026) & (MT) Table 57. Global Vaccine Adjuvants Sales Market Share by Country (2021-2026) Table 58. Global Vaccine Adjuvants Sales by Country (2027-2032) & (MT) Table 59. Global Vaccine Adjuvants Sales Market Share by Country (2027-2032) Table 60. Global Vaccine Adjuvants Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Vaccine Adjuvants Sales Value Market Share by Country (2021-2026) Table 62. Global Vaccine Adjuvants Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Vaccine Adjuvants Sales Value Market Share by Country (2027-2032) Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 67. GSK Vaccine Adjuvants Product Portfolio Table 68. GSK Recent Development Table 69. CSL Limited Company Information Table 70. CSL Limited Business Overview Table 71. CSL Limited Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 72. CSL Limited Vaccine Adjuvants Product Portfolio Table 73. CSL Limited Recent Development Table 74. Croda Company Information Table 75. Croda Business Overview Table 76. Croda Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 77. Croda Vaccine Adjuvants Product Portfolio Table 78. Croda Recent Development Table 79. SEPPIC Company Information Table 80. SEPPIC Business Overview Table 81. SEPPIC Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 82. SEPPIC Vaccine Adjuvants Product Portfolio Table 83. SEPPIC Recent Development Table 84. Novavax Company Information Table 85. Novavax Business Overview Table 86. Novavax Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 87. Novavax Vaccine Adjuvants Product Portfolio Table 88. Novavax Recent Development Table 89. SPI Pharma Company Information Table 90. SPI Pharma Business Overview Table 91. SPI Pharma Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 92. SPI Pharma Vaccine Adjuvants Product Portfolio Table 93. SPI Pharma Recent Development Table 94. Phibro Company Information Table 95. Phibro Business Overview Table 96. Phibro Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 97. Phibro Vaccine Adjuvants Product Portfolio Table 98. Phibro Recent Development Table 99. SDA BIO Company Information Table 100. SDA BIO Business Overview Table 101. SDA BIO Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 102. SDA BIO Vaccine Adjuvants Product Portfolio Table 103. SDA BIO Recent Development Table 104. Invivogen Company Information Table 105. Invivogen Business Overview Table 106. Invivogen Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 107. Invivogen Vaccine Adjuvants Product Portfolio Table 108. Invivogen Recent Development Table 109. Tj Kaiwei Company Information Table 110. Tj Kaiwei Business Overview Table 111. Tj Kaiwei Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 112. Tj Kaiwei Vaccine Adjuvants Product Portfolio Table 113. Tj Kaiwei Recent Development Table 114. OZ Biosciences Company Information Table 115. OZ Biosciences Business Overview Table 116. OZ Biosciences Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 117. OZ Biosciences Vaccine Adjuvants Product Portfolio Table 118. OZ Biosciences Recent Development Table 119. Brenntag Biosector Company Information Table 120. Brenntag Biosector Business Overview Table 121. Brenntag Biosector Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 122. Brenntag Biosector Vaccine Adjuvants Product Portfolio Table 123. Brenntag Biosector Recent Development Table 124. MVP Laboratories Company Information Table 125. MVP Laboratories Business Overview Table 126. MVP Laboratories Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 127. MVP Laboratories Vaccine Adjuvants Product Portfolio Table 128. MVP Laboratories Recent Development Table 129. Zhuoyue Company Information Table 130. Zhuoyue Business Overview Table 131. Zhuoyue Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 132. Zhuoyue Vaccine Adjuvants Product Portfolio Table 133. Zhuoyue Recent Development Table 134. Aphios Company Information Table 135. Aphios Business Overview Table 136. Aphios Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 137. Aphios Vaccine Adjuvants Product Portfolio Table 138. Aphios Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Vaccine Adjuvants Distributors List Table 142. Vaccine Adjuvants Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Vaccine Adjuvants Product Image Figure 2. Global Vaccine Adjuvants Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vaccine Adjuvants Sales (2021-2032) & (MT) Figure 5. Global Vaccine Adjuvants Sales Average Price (USD/Kg) & (2021-2032) Figure 6. Global Vaccine Adjuvants Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Aluminum Adjuvant Image Figure 10. Emulsions Adjuvant Image Figure 11. Others Image Figure 12. Global Vaccine Adjuvants Sales Volume by Type (2021 VS 2025 VS 2032) & (MT) Figure 13. Global Vaccine Adjuvants Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Vaccine Adjuvants Sales Volume Share by Type (2021-2032) Figure 15. Global Vaccine Adjuvants Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Vaccine Adjuvants Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Vaccine Adjuvants Sales Value Share by Type (2021-2032) Figure 18. Human Vaccine Image Figure 19. Veterinary Vaccine Image Figure 20. Global Vaccine Adjuvants Sales Volume by Application (2021 VS 2025 VS 2032) & (MT) Figure 21. Global Vaccine Adjuvants Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Vaccine Adjuvants Sales Volume Share by Application (2021-2032) Figure 23. Global Vaccine Adjuvants Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Vaccine Adjuvants Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Vaccine Adjuvants Sales Value Share by Application (2021-2032) Figure 26. Global Vaccine Adjuvants Sales by Region: 2021 VS 2025 VS 2032 (MT) Figure 27. Global Vaccine Adjuvants Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Vaccine Adjuvants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Vaccine Adjuvants Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Vaccine Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 31. North America Vaccine Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Vaccine Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Vaccine Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Vaccine Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Vaccine Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Vaccine Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 37. South America Vaccine Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Vaccine Adjuvants Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Vaccine Adjuvants Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Vaccine Adjuvants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Vaccine Adjuvants Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Vaccine Adjuvants Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Aluminum Adjuvant
  • Emulsions Adjuvant
  • Others
Applications
  • Human Vaccine
  • Veterinary Vaccine
Companies covered
  • GSK
  • CSL Limited
  • Croda
  • SEPPIC
  • Novavax
  • SPI Pharma
  • Phibro
  • SDA BIO
  • Invivogen
  • Tj Kaiwei
  • OZ Biosciences
  • Brenntag Biosector
  • MVP Laboratories
  • Zhuoyue
  • Aphios

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaccine Adjuvants Sales Value (2021-2032)
  4. 1.2.2 Global Vaccine Adjuvants Sales Volume (2021-2032)
  5. 1.2.3 Global Vaccine Adjuvants Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vaccine Adjuvants Market Dynamics
  1. 2.1 Vaccine Adjuvants Industry Trends
  2. 2.2 Vaccine Adjuvants Industry Drivers
  3. 2.3 Vaccine Adjuvants Industry Opportunities and Challenges
  4. 2.4 Vaccine Adjuvants Industry Restraints
3 Vaccine Adjuvants Market by Company
  1. 3.1 Global Vaccine Adjuvants Company Revenue Ranking in 2025
  2. 3.2 Global Vaccine Adjuvants Revenue by Company (2021-2026)
  3. 3.3 Global Vaccine Adjuvants Sales Volume by Company (2021-2026)
  4. 3.4 Global Vaccine Adjuvants Average Price by Company (2021-2026)
  5. 3.5 Global Vaccine Adjuvants Company Ranking (2024-2026)
  6. 3.6 Global Vaccine Adjuvants Company Manufacturing Base and Headquarters
  7. 3.7 Global Vaccine Adjuvants Company Product Type and Application
  8. 3.8 Global Vaccine Adjuvants Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vaccine Adjuvants Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vaccine Adjuvants Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vaccine Adjuvants Market by Type
  1. 4.1 Vaccine Adjuvants Type Introduction
  2. 4.1.1 Aluminum Adjuvant
  3. 4.1.2 Emulsions Adjuvant
  4. 4.1.3 Others
  5. 4.2 Global Vaccine Adjuvants Sales Volume by Type
  6. 4.2.1 Global Vaccine Adjuvants Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Vaccine Adjuvants Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Vaccine Adjuvants Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Vaccine Adjuvants Sales Value by Type
  10. 4.3.1 Global Vaccine Adjuvants Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Vaccine Adjuvants Sales Value by Type (2021-2032)
  12. 4.3.3 Global Vaccine Adjuvants Sales Value Share by Type (2021-2032)
5 Vaccine Adjuvants Market by Application
  1. 5.1 Vaccine Adjuvants Application Introduction
  2. 5.1.1 Human Vaccine
  3. 5.1.2 Veterinary Vaccine
  4. 5.2 Global Vaccine Adjuvants Sales Volume by Application
  5. 5.2.1 Global Vaccine Adjuvants Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine Adjuvants Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Vaccine Adjuvants Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Vaccine Adjuvants Sales Value by Application
  9. 5.3.1 Global Vaccine Adjuvants Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vaccine Adjuvants Sales Value by Application (2021-2032)
  11. 5.3.3 Global Vaccine Adjuvants Sales Value Share by Application (2021-2032)
6 Vaccine Adjuvants Regional Sales and Value Analysis
  1. 6.1 Global Vaccine Adjuvants Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine Adjuvants Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine Adjuvants Sales by Region: 2021-2026
  4. 6.2.2 Global Vaccine Adjuvants Sales by Region (2027-2032)
  5. 6.3 Global Vaccine Adjuvants Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vaccine Adjuvants Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vaccine Adjuvants Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vaccine Adjuvants Sales Value by Region (2027-2032)
  9. 6.5 Global Vaccine Adjuvants Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vaccine Adjuvants Sales Value (2021-2032)
  12. 6.6.2 North America Vaccine Adjuvants Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vaccine Adjuvants Sales Value (2021-2032)
  15. 6.7.2 Europe Vaccine Adjuvants Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vaccine Adjuvants Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vaccine Adjuvants Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vaccine Adjuvants Sales Value (2021-2032)
  21. 6.9.2 South America Vaccine Adjuvants Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vaccine Adjuvants Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vaccine Adjuvants Sales Value Share by Country, 2025 VS 2032
7 Vaccine Adjuvants Country-level Sales and Value Analysis
  1. 7.1 Global Vaccine Adjuvants Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaccine Adjuvants Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vaccine Adjuvants Sales by Country (2021-2032)
  4. 7.3.1 Global Vaccine Adjuvants Sales by Country (2021-2026)
  5. 7.3.2 Global Vaccine Adjuvants Sales by Country (2027-2032)
  6. 7.4 Global Vaccine Adjuvants Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vaccine Adjuvants Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vaccine Adjuvants Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vaccine Adjuvants Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vaccine Adjuvants Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vaccine Adjuvants Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Vaccine Adjuvants Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 CSL Limited
  8. 8.2.1 CSL Limited Company Information
  9. 8.2.2 CSL Limited Business Overview
  10. 8.2.3 CSL Limited Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSL Limited Vaccine Adjuvants Product Portfolio
  12. 8.2.5 CSL Limited Recent Developments
  13. 8.3 Croda
  14. 8.3.1 Croda Company Information
  15. 8.3.2 Croda Business Overview
  16. 8.3.3 Croda Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Croda Vaccine Adjuvants Product Portfolio
  18. 8.3.5 Croda Recent Developments
  19. 8.4 SEPPIC
  20. 8.4.1 SEPPIC Company Information
  21. 8.4.2 SEPPIC Business Overview
  22. 8.4.3 SEPPIC Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 SEPPIC Vaccine Adjuvants Product Portfolio
  24. 8.4.5 SEPPIC Recent Developments
  25. 8.5 Novavax
  26. 8.5.1 Novavax Company Information
  27. 8.5.2 Novavax Business Overview
  28. 8.5.3 Novavax Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novavax Vaccine Adjuvants Product Portfolio
  30. 8.5.5 Novavax Recent Developments
  31. 8.6 SPI Pharma
  32. 8.6.1 SPI Pharma Company Information
  33. 8.6.2 SPI Pharma Business Overview
  34. 8.6.3 SPI Pharma Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SPI Pharma Vaccine Adjuvants Product Portfolio
  36. 8.6.5 SPI Pharma Recent Developments
  37. 8.7 Phibro
  38. 8.7.1 Phibro Company Information
  39. 8.7.2 Phibro Business Overview
  40. 8.7.3 Phibro Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Phibro Vaccine Adjuvants Product Portfolio
  42. 8.7.5 Phibro Recent Developments
  43. 8.8 SDA BIO
  44. 8.8.1 SDA BIO Company Information
  45. 8.8.2 SDA BIO Business Overview
  46. 8.8.3 SDA BIO Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 SDA BIO Vaccine Adjuvants Product Portfolio
  48. 8.8.5 SDA BIO Recent Developments
  49. 8.9 Invivogen
  50. 8.9.1 Invivogen Company Information
  51. 8.9.2 Invivogen Business Overview
  52. 8.9.3 Invivogen Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Invivogen Vaccine Adjuvants Product Portfolio
  54. 8.9.5 Invivogen Recent Developments
  55. 8.10 Tj Kaiwei
  56. 8.10.1 Tj Kaiwei Company Information
  57. 8.10.2 Tj Kaiwei Business Overview
  58. 8.10.3 Tj Kaiwei Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Tj Kaiwei Vaccine Adjuvants Product Portfolio
  60. 8.10.5 Tj Kaiwei Recent Developments
  61. 8.11 OZ Biosciences
  62. 8.11.1 OZ Biosciences Company Information
  63. 8.11.2 OZ Biosciences Business Overview
  64. 8.11.3 OZ Biosciences Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 OZ Biosciences Vaccine Adjuvants Product Portfolio
  66. 8.11.5 OZ Biosciences Recent Developments
  67. 8.12 Brenntag Biosector
  68. 8.12.1 Brenntag Biosector Company Information
  69. 8.12.2 Brenntag Biosector Business Overview
  70. 8.12.3 Brenntag Biosector Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Brenntag Biosector Vaccine Adjuvants Product Portfolio
  72. 8.12.5 Brenntag Biosector Recent Developments
  73. 8.13 MVP Laboratories
  74. 8.13.1 MVP Laboratories Company Information
  75. 8.13.2 MVP Laboratories Business Overview
  76. 8.13.3 MVP Laboratories Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 MVP Laboratories Vaccine Adjuvants Product Portfolio
  78. 8.13.5 MVP Laboratories Recent Developments
  79. 8.14 Zhuoyue
  80. 8.14.1 Zhuoyue Company Information
  81. 8.14.2 Zhuoyue Business Overview
  82. 8.14.3 Zhuoyue Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Zhuoyue Vaccine Adjuvants Product Portfolio
  84. 8.14.5 Zhuoyue Recent Developments
  85. 8.15 Aphios
  86. 8.15.1 Aphios Company Information
  87. 8.15.2 Aphios Business Overview
  88. 8.15.3 Aphios Vaccine Adjuvants Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Aphios Vaccine Adjuvants Product Portfolio
  90. 8.15.5 Aphios Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine Adjuvants Value Chain Analysis
  2. 9.1.1 Vaccine Adjuvants Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine Adjuvants Sales Mode & Process
  6. 9.2 Vaccine Adjuvants Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine Adjuvants Distributors
  9. 9.2.3 Vaccine Adjuvants Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst